Healthcare Wrap: Debt Deals, FDA Wins and Revenue Growth Drive Week 28 Movers

• Argent BioPharma doubled after a CannEpil licensing deal wiped out secured debt and added a royalty stream.
• Imugene fell despite raising cash, as traders sold into the stock after a sharp re-opening jump.
• Island Pharmaceuticals surged on Ebola-related Galidesivir progress, but much of the early gain faded during the week.
• Mesoblast, Compumedics and Cogstate all pointed to growing healthcare demand through sales, backlog or recurring revenue.